Matthew Lang Lyell Immunopharma, Inc. (LYEL) insider trading activity

LYEL Quotes by TradingView

Matthew Lang is Chief Business Officer of Lyell Immunopharma, Inc.. Currently has a direct ownership of 162,500 shares of LYEL, which is worth approximately $120,250. The most recent transaction as insider was on Feb 10, 2025, when has been sold 112,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 163K
225.0% 3M change
225.0% 12M change
Total Value Held $120,250

Matthew Lang Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 10 2025
BUY
Grant, award, or other acquisition
-
112,500 Added 40.91%
162,500 Common Stock
Feb 09 2024
BUY
Grant, award, or other acquisition
-
50,000 Added 50.0%
50,000 Common Stock

Also insider at

MYOV
Myovant Sciences Ltd. Healthcare
General Counsel & Corp. Secy.
ML

Matthew Lang

Chief Business Officer
Brisbane, CA

Track Institutional and Insider Activities on LYEL

Follow Lyell Immunopharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LYEL shares.

Notify only if

Insider Trading

Get notified when an Lyell Immunopharma, Inc. insider buys or sells LYEL shares.

Notify only if

News

Receive news related to Lyell Immunopharma, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on LYEL